Zevra Therapeutics
ZVRA
71 hedge funds and large institutions have $41.6M invested in Zevra Therapeutics in 2023 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 13 closing their positions.
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
40% more call options, than puts
Call options by funds: $2.71M | Put options by funds: $1.93M
23% more capital invested
Capital invested by funds: $33.8M → $41.6M (+$7.75M)
18% more funds holding
Funds holding: 60 → 71 (+11)
6.32% more ownership
Funds ownership: 17.75% → 24.07% (+6.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.62M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.61M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.9M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.17M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$736K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$3.14M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.91M |
| 3 |
Jane Street
New York
|
-$1.02M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$859K |
| 5 |
Millennium Management
New York
|
-$842K |
ZVRA Hedge Fund Activity: Q2 2023 in Review
71 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q2 2023, worth a combined $41.6M — up 23% from $33.8M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ZVRA positions and 13 closed out — a net gain of 11 holders — while 19 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $8.62M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $3.14M sold.
- 71 institutional investors held Zevra Therapeutics (ZVRA) as of Q2 2023, up from 60 in Q1 2023.
- Funds reported $41.6M of Zevra Therapeutics stock for Q2 2023, up 23% quarter-over-quarter.
- 24 funds opened new Zevra Therapeutics positions in Q2 2023 and 13 closed out, a net change of +11 holders.
- The largest Zevra Therapeutics buyer in Q2 2023 was BlackRock, an estimated $8.62M added.
- The largest Zevra Therapeutics seller in Q2 2023 was Laurion Capital Management, an estimated $3.14M sold.
Based on aggregated 13F filings for Q2 2023.